Please login to the form below

Not currently logged in
Email:
Password:

paliperidone palmitate

This page shows the latest paliperidone palmitate news and features for those working in and with pharma, biotech and healthcare.

Allergan and Gedeon finally get antipsychotic green light

Allergan and Gedeon finally get antipsychotic green light

Once-monthly examples include Otsuka/Lundbeck's Abilify Maintena (aripiprazole) and Johnson and Johnson's Invega Sustenna (paliperidone palmitate), while J&J is also developing a three-monthly paliperidone depot that

Latest news

  • More waiting for Allergan and Gedeon Richter's antipsychotic More waiting for Allergan and Gedeon Richter's antipsychotic

    The drug is one of several new antipsychotic agents expected to drive growth in the schizophrenia market in the coming years, along with Johnson &Johnson's three-monthly paliperidone palmitate depot,

  • FDA approves J&J’s schizophrenia drug Invega Trinza FDA approves J&J’s schizophrenia drug Invega Trinza

    The FDA has approved Johnson &Johnson's Invega Trinza (three-month paliperidone palmitate) for schizophrenia. ... Before patients can be started on the drug they must first be taking Janssen's Invega Sustenna, a one-month form of paliperidone palmitate,

  • J&J gets quicker review for schizophrenia depot in US J&J gets quicker review for schizophrenia depot in US

    The US FDA has granted priority review status to Johnson &Johnson's paliperidone palmitate depot, which if approved will become the first schizophrenia drug that can be administered just four times ... The current formulation of paliperidone - sold as

  • Double win for J&J's schizophrenia franchise Double win for J&J's schizophrenia franchise

    Added to that, the pharma company has just stopped a trial of its three-monthly formulation of Risperdal (risperidone) follow-up paliperidone palmitate on positive results, setting up a filing later ... Three-monthly paliperidone. Meanwhile, J&J could

  • OTC recovery helps J&J in first-quarter OTC recovery helps J&J in first-quarter

    The company said the sales increase was also helped by new pharmaceutical product introductions, including its depot antipsychotic Invega Sustenna/Xeplion (paliperidone palmitate), which grew 76 per cent to $284m in

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics